Changes in Manufacturing Processes of Biologic Therapies Can Alter the Immunogenicity Profile of the Product

MLA

Abdelkader Rahmaoui, et al. “Changes in Manufacturing Processes of Biologic Therapies Can Alter the Immunogenicity Profile of the Product.” Clinical Pharmacology and Therapeutics, vol. 107, no. 4, Dec. 2019, pp. 988–93. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9e642f8f057234b962a813ded8d1c192&authtype=sso&custid=ns315887.

APA

Abdelkader Rahmaoui, Aristides Maniatis, Dalia Moawad, Valerie Quarmby, Linda Yau, Martin Vanderlaan, Craig Azzolino, Cynthia Woods, & Robert C. Olney. (2019). Changes in Manufacturing Processes of Biologic Therapies Can Alter the Immunogenicity Profile of the Product. Clinical Pharmacology and Therapeutics, 107(4), 988–993.

Chicago

Abdelkader Rahmaoui, Aristides Maniatis, Dalia Moawad, Valerie Quarmby, Linda Yau, Martin Vanderlaan, Craig Azzolino, Cynthia Woods, and Robert C. Olney. 2019. “Changes in Manufacturing Processes of Biologic Therapies Can Alter the Immunogenicity Profile of the Product.” Clinical Pharmacology and Therapeutics 107 (4): 988–93. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9e642f8f057234b962a813ded8d1c192&authtype=sso&custid=ns315887.